Con esta herramienta te facilitamos un acceso a todas las ofertas y demandas de tecnología europeas y a búsquedas de socios para participar en propuestas europeas de I+D publicadas en la red Enterprise Europe Network, pudiendo filtrar los resultados para facilitar las búsquedas más acordes con tus necesidades.

¿Quieres recibir estos listados de oportunidades de colaboración en tu correo de forma periódica y personalizada? Date de alta en nuestro Boletín

Para optimizar los resultados de la búsqueda, se recomienda utilizar términos en inglés.

Oficina francesa de transferencia de tecnología ofrece un nuevo bloqueador potente del receptor HER2 para el tratamiento del cáncer de mama metastásico

Resumen

Tipo:
Oferta Tecnológica
Referencia:
TOFR20171005001
Publicado:
20/11/2017
Caducidad:
20/11/2018
Resumen:
Una oficina de transferencia de tecnología de una universidad francesa ofrece un potente bloqueador del receptor HER2 para el tratamiento de la metástasis cerebral del cáncer de mama, tratamiento contra la resistencia a cánceres de mama HER2+ y tratamiento potencial para otros cánceres HER2+ (cánceres de ovario, estómago, glándulas salivales, neuroblastoma, etc.). Las dos familias de compuestos desarrolladas pueden cruzar la barrera hematoencefálica y llegar hasta la metástasis cerebral. La universidad busca compañías para licenciar la tecnología o cooperar en materia de investigación.

Details

Tittle:
French Technology Transfer Office offers new potent blocker of HER2 receptor for treatment of metastatic breast cancer
Summary:
A French Unviversity (Technology Transfer Office) offers a new potent blocker of HER2 receptor for :
- the treatment of breast cancer´s brain metastases
- the treatment against HER2+ breast cancers resistance
- the potential treatment of other HER2+ cancers (ovarian, gastric, salivary, neuroblastoma etc).
The TTO of this University is looking for companies to license in this technology or for research cooperation.
Description:
The French TTO (Technology Transfer Office) is acting on behalf of an established public laboratory of an university of the Paris region.

Breast cancer is the top cancer in women worldwide and is increasing particularly in developing countries where the majority of cases are diagnosed in late stages.1.7 million new cases of breast cancer occurred among women worldwide in 2012 (most recent data available)

20 to 30% of breast cancers are related to an overexpression of HER2 and among them, 20 to 40% express p95HER2, a truncated version of the receptor believed to play a role in cancer resistance.

Despite the benefits of the recent therapies targeting HER2 (Herceptin®, Perjeta® and Tykerb®), a large part of patients relapses because of treatment failure due to cancer resistance or toxicity issues. Notably, 20% to 50% of HER2 metastatic breast cancer patients die of brain metastases.

It was recently found that targeting a new domain of HER2 prevents the activation of HER2 signalization and may constitute a novel therapeutic approach. The present offer proposes two compound families targeting this domain and inhibiting specifically HER2 downstream signaling pathways in breast cancer. The compounds are able to cross the blood-brain barrier and, therefore, to target brain metastases.

The TTO of this University is looking for companies or universities in order to license this technology or to collaborate in its development.
Advantages and Innovations:
New intracellular target domain on HER2 protein
Effective on HER2 wild type as well as known drug resistant mutants such as p95HER2
Small molecules crossing the Blood-Brain Barrier to target brain metastases
Stage of Development:
Available for demonstration
IPs:
Patents granted
CommeR Statunts Regarding IPR Status:
Priority patent application, filed on January 2016

Partner sought

Type and Role of Partner Sought:
The partner sought could be an university or a company interested in a license agreement or a research cooperation agreement or a technical cooperation agreement

Client

Type and Size of Client:
University
Already Engaged in Trans-National Cooperation:
Si
Languages Spoken:
English
French

Keywords

Technology Keywords:
06001003 Citología, cancerología, oncología